Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused?

Robert Kemp, Vinay Prasad

Research output: Contribution to journalArticlepeer-review

112 Scopus citations

Fingerprint

Dive into the research topics of 'Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused?'. Together they form a unique fingerprint.

Medicine & Life Sciences